MX2019014026A - Metodos para la deteccion de melanoma. - Google Patents

Metodos para la deteccion de melanoma.

Info

Publication number
MX2019014026A
MX2019014026A MX2019014026A MX2019014026A MX2019014026A MX 2019014026 A MX2019014026 A MX 2019014026A MX 2019014026 A MX2019014026 A MX 2019014026A MX 2019014026 A MX2019014026 A MX 2019014026A MX 2019014026 A MX2019014026 A MX 2019014026A
Authority
MX
Mexico
Prior art keywords
methods
melanoma
melanoma detection
subject
detection
Prior art date
Application number
MX2019014026A
Other languages
English (en)
Spanish (es)
Inventor
Mark Kidd
Irvin Modlin
Ignat Drozdov
Original Assignee
Liquid Biopsy Res Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Liquid Biopsy Res Llc filed Critical Liquid Biopsy Res Llc
Publication of MX2019014026A publication Critical patent/MX2019014026A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5751—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the skin, e.g. melanoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2563/00—Nucleic acid detection characterized by the use of physical, structural and functional properties
    • C12Q2563/107—Nucleic acid detection characterized by the use of physical, structural and functional properties fluorescence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7023—(Hyper)proliferation
    • G01N2800/7028—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
MX2019014026A 2017-05-25 2018-05-21 Metodos para la deteccion de melanoma. MX2019014026A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762511058P 2017-05-25 2017-05-25
PCT/US2018/033658 WO2018217627A1 (en) 2017-05-25 2018-05-21 Methods for melanoma detection

Publications (1)

Publication Number Publication Date
MX2019014026A true MX2019014026A (es) 2020-08-03

Family

ID=62620988

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019014026A MX2019014026A (es) 2017-05-25 2018-05-21 Metodos para la deteccion de melanoma.

Country Status (13)

Country Link
US (3) US20180340934A1 (cg-RX-API-DMAC7.html)
EP (1) EP3631017B1 (cg-RX-API-DMAC7.html)
JP (1) JP7227964B2 (cg-RX-API-DMAC7.html)
KR (1) KR102763004B1 (cg-RX-API-DMAC7.html)
CN (1) CN111315897B (cg-RX-API-DMAC7.html)
AU (1) AU2018273844B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019024481A2 (cg-RX-API-DMAC7.html)
DK (1) DK3631017T3 (cg-RX-API-DMAC7.html)
ES (1) ES2920288T3 (cg-RX-API-DMAC7.html)
IL (1) IL270787B2 (cg-RX-API-DMAC7.html)
MX (1) MX2019014026A (cg-RX-API-DMAC7.html)
PL (1) PL3631017T3 (cg-RX-API-DMAC7.html)
WO (1) WO2018217627A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019014026A (es) 2017-05-25 2020-08-03 Liquid Biopsy Res Llc Metodos para la deteccion de melanoma.
EP4041886A1 (en) 2019-10-10 2022-08-17 Liquid Biopsy Research LLC Compositions, methods and kits for biological sample and rna stabilization

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006203830A1 (en) * 2005-01-07 2006-07-13 The Johins Hopkins University Biomarkers for melanoma
WO2008031041A2 (en) * 2006-09-07 2008-03-13 H. Lee Moffitt Cancer Center And Research Institute, Inc. Melanoma gene signature
NZ576428A (en) * 2006-11-03 2012-04-27 Baylor Res Inst Diagnosis of metastatic melanoma and monitoring indicators of immunosuppression through blood leukocyte microarray analysis
EP2092075A2 (en) 2006-11-06 2009-08-26 Source Precision Medicine, Inc. Gene expression profiling for identification, monitoring and treatment of melanoma
US20110070582A1 (en) 2008-11-03 2011-03-24 Source Precision Medicine, Inc. d/b/d Source MDX Gene Expression Profiling for Predicting the Response to Immunotherapy and/or the Survivability of Melanoma Subjects
CN102667484A (zh) * 2009-10-13 2012-09-12 约翰·霍普金斯大学 识别黑素瘤肿瘤细胞的生物标记
WO2012031008A2 (en) 2010-08-31 2012-03-08 The General Hospital Corporation Cancer-related biological materials in microvesicles
WO2014008270A1 (en) * 2012-07-03 2014-01-09 Ratiopharm Gmbh Solid state form of vemurafenib choline salt
US10407730B2 (en) * 2014-09-15 2019-09-10 Clifton Life Sciences LLC Compositions, methods and kits for diagnosis of a gastroenteropancreatic neuroendocrine neoplasm
MX2019014026A (es) 2017-05-25 2020-08-03 Liquid Biopsy Res Llc Metodos para la deteccion de melanoma.

Also Published As

Publication number Publication date
EP3631017A1 (en) 2020-04-08
JP7227964B2 (ja) 2023-02-22
DK3631017T3 (da) 2022-06-20
US20260202409A1 (en) 2026-07-16
IL270787B1 (en) 2023-04-01
PL3631017T3 (pl) 2022-09-26
CN111315897A (zh) 2020-06-19
ES2920288T3 (es) 2022-08-02
BR112019024481A2 (pt) 2020-07-14
WO2018217627A1 (en) 2018-11-29
US20180340934A1 (en) 2018-11-29
CA3064732A1 (en) 2018-11-29
IL270787B2 (en) 2023-08-01
IL270787A (en) 2020-01-30
KR20200030034A (ko) 2020-03-19
AU2018273844B2 (en) 2024-11-14
CN111315897B (zh) 2024-10-22
US20230022236A1 (en) 2023-01-26
KR102763004B1 (ko) 2025-02-04
US12399179B2 (en) 2025-08-26
JP2020524524A (ja) 2020-08-20
AU2018273844A1 (en) 2019-12-19
EP3631017B1 (en) 2022-03-23

Similar Documents

Publication Publication Date Title
CL2017002604A1 (es) Sondas duales silenciadoras
CY1121341T1 (el) Δοκιμες για την ανιχνευση της παρουσιας ή της ποσοτητας αντισωματος κατα αντισωματος φαρμακου
BR112016006319A2 (pt) inibidores de irak e usos dos mesmos
MX2017005920A (es) Anticuerpos anti-tim3 y metodos de uso.
BR112015022763A8 (pt) sensor para detectar um analito
CL2017000590A1 (es) Anticuerpos anti-cll-1 e inmunoconjugados
CR20160500A (es) Anticuerpos anti-ox40 y métodos de uso
CL2016001432A1 (es) Nuevos anticuerpos anti-dpep3 y métodos de uso
ECSP13012786A (es) Anticuerpos anti-pcsk9 y métodos de uso
ES2570380T3 (es) Método para determinar la aptitud de inhibidores de EZH2 humano en tratamiento
CR20150462A (es) Inhibidores de erk y sus usos
MX2017005888A (es) Dispositivos, sistemas y metodos para la deteccion de analitos.
BR112015032224A2 (pt) anticorpos anti-fcrh5
MX2017007049A (es) Anticuerpos anti-cd79b y métodos de uso.
MX2017015464A (es) Anticuerpos anti-tau y metodos de uso.
CR20160270A (es) ANTICUERPOS ANTI-TAU (pS422) HUMANIZADOS Y MÉTODOS DE UTILIZACIÓN
CO7151531A2 (es) Anticuerpos e inmunoconjugados contra ly6e y métodos de uso
MX380146B (es) Inhibidores mk2 y usos de los mismos.
MX2016002423A (es) Composiciones y metodos de diagnostico para el tratamiento de glioblastoma.
ECSP13012784A (es) Anticuerpos anti-mesotelina e inmunoconjugados
BR112013004490A2 (pt) aparelho para medir propriedade termodinâmicas de fluidos de reservatório, e método para medir propriedades termodinâmicas de fluidos de reservatório
MX2016010433A (es) Anticuerpos anti-jagged1 y metodos de uso.
CR20150247A (es) Anticuerpos de antihemaglutinina y métodos de uso
EA201692541A1 (ru) Вакцины против вируса гриппа и их применения
BR112015023026A2 (pt) indicador de esterilização para esterilizantes oxidativos e processo para determinar a eficácia de um processo de esterilização utilizando esterilizantes oxidativos